rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TNGX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Tango Therapeutics R&D president Adam Crystal sells $125,000 in stock
      Nov 14Investing.comTNGX
      Tango Therapeutics Stock Has The Bull Case Changed After JPMorgan Backing

      Tango Therapeutics reported a third quarter 2026 net loss of US$68.39 million and a nine month loss of US$169.25 million, while moving its precision oncology pipeline forward. The new Phase 1/2 combination trial of vopimetostat with ERAS-0015 in MTAP-deleted pancreatic and lung cancers deepens Tango Therapeutics' focus on MTAP-driven tumor biology despite higher recent losses. We will now look at how Tango Therapeutics' investment narrative is affected by deeper vopimetostat combinations...

      Nov 12Yahoo FinanceTNGXJPM
      Jefferies raises Tango Therapeutics stock price target on trial data
      Nov 10Investing.comTNGX
      JPMorgan raises Tango Therapeutics price target to $47 on pipeline
      Nov 10Investing.comTNGX
      Tango Therapeutics earnings on deck after ESMO data readout
      Nov 9Investing.comTNGX
      Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights

      Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free survival (PFS) rate in patients with 2L/3L pancreatic cancer; combination was generally well-tolerated at go-forward dose Registrational Phase 3 study of vopimetostat plus daraxonrasib as front-line treatment for patients with MTAP-deleted pancreatic cancer expected to be initiated in 1H 2027 Data from vo

      Nov 9Yahoo FinanceTNGX
      Tango Therapeutics president sells $112,107 in shares
      Nov 5Investing.comTNGX
      Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference
      Nov 3Yahoo FinanceTNGX
      Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data (TNGX)

      Tango Therapeutics combination therapy showed an 82% ORR and 88% 9-month PFS, with median PFS not yet reached, supporting advancement to Phase 3. Learn more about TNGX stock here.

      Oct 30Seeking AlphaRVMDTNGX
      Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying
      Oct 28Seeking AlphaTNGX
      Tango Therapeutics (TNGX) Following Trial Update Has Its Valuation Story Back In Focus
      Oct 28Yahoo FinanceTNGX
      Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside?
      Oct 28Yahoo FinanceTNGX
      Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer - Slideshow (NASDAQ:TNGX) 2026-10-27
      Oct 27Seeking AlphaTNGX
      Canaccord Genuity Remains a Buy on Tango Therapeutics (TNGX)

      Detailed price information for Tango Therapeutics Inc (TNGX-Q) from The Globe and Mail including charting and trades.

      Oct 27The Globe and MailTNGX
      TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data
      Oct 26Yahoo FinanceTNGX
      Wedbush raises Tango Therapeutics stock price target on trial data
      Oct 23Investing.comTNGX
      Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate
      Oct 23Yahoo FinanceTNGX
      Stifel raises Tango Therapeutics stock price target on trial data
      Oct 23Investing.comTNGX
      Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?
      Oct 23BenzingaTNGX
      Wedbush Adjusts Price Target on Tango Therapeutics to $45 From $39, Maintains Outperform Rating
      Oct 23Yahoo FinanceTNGX
      Why is Tango Therapeutics stock sliding today?
      Oct 23Investing.comTNGX
      Tango Therapeutics stock falls despite positive cancer trial data
      Oct 23Investing.comTNGX
      Tango Therapeutics reports pancreatic cancer trial data
      Oct 23Investing.comTNGX
      How Tango Improved On Revolution's 'Unprecedented' Results

      Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer.

      Oct 23Investor's Business DailyRVMDTNGX
      Tango Therapeutics Sinks 13% on Pancreatic Cancer Data It Says “Surpass Any Published PDAC Datasets”
      Oct 23Yahoo FinanceRVMDTNGX
      Tango Therapeutics (TNGX) Stock Looks Fully Valued After A 252% Run
      Oct 21Yahoo FinanceTNGX
      Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In?
      Oct 20Yahoo FinanceTNGX
      Tango Therapeutics to present pancreatic cancer study data
      Oct 16Investing.comTNGX
      Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
      Oct 16Yahoo FinanceTNGX
      Tango Therapeutics stock initiated at outperform by William Blair
      Oct 16Investing.comTNGX
      JPMorgan reiterates Tango Therapeutics stock rating ahead of ESMO data
      Oct 13Investing.comTNGX
      Tango Therapeutics R&D president Adam Crystal sells $660,796 in shares
      Oct 12Investing.comTNGX
      Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Glaukos (GKOS) and Pfizer (PFE)

      Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailTNGXGKOS
      Tango therapeutics R&D president Adam Crystal sells $660k in shares.
      Oct 5Investing.comTNGX
      Tango Therapeutics Insider Sold Shares Worth $660,796, According to a Recent SEC Filing
      Oct 5Yahoo FinanceTNGX
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Tango Therapeutics (TNGX), Neurocrine (NBIX) and United Therapeutics (UTHR)

      Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailNBIXTNGX
      Tango Therapeutics (TNGX) Receives a Buy from Guggenheim

      Detailed price information for Tango Therapeutics Inc (TNGX-Q) from The Globe and Mail including charting and trades.

      Sep 25The Globe and MailTNGX
      Tango Therapeutics principal accounting officer sells $198k in stock
      Sep 25Investing.comTNGX
      Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

      Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Sep 10Yahoo FinanceTNGX
      Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path
      Sep 9Investing.comTNGX
      Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey

      Tango Therapeutics stock reaction and recent performance Tango Therapeutics (TNGX) has drawn investor attention after recent trading moves, with the stock closing at US$22.76 on the latest trading day. The price change offers a fresh prompt to reassess the company’s recent performance. Over the past month, Tango Therapeutics stock has fallen about 22%, while the past 3 months show a gain of roughly 13%. Year to date, the stock return is about 155%, and the 1-year total return is about...

      Sep 4Yahoo FinanceTNGX
      Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan. The Tango Therapeutics 2023 Inducement Plan is used exclusively for th

      Sep 3Yahoo FinanceTNGX
      Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

      BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be a

      Sep 1Yahoo FinanceTNGX

      This is the newest page. Registered accounts read further back.